HR+/HER2- Early Breast Cancer

HR+/HER2- Early Breast Cancer

Surveillance Expectations for Early-Stage Breast Cancer

patient care perspectives
By Virginia Kaklamani, MD, DSc

HR+/HER2- Early Breast Cancer

Adjuvant CDK4/6 Inhibitors for HR+/HER2- Early-Stage Breast Cancer: Who Should Get Them and How Toxicity Should Be Managed

clinical topic updates
By Ian Krop, MD, PhD

HR+/HER2- Early Breast Cancer

Breast Cancer Risk Assessment and Reduction Strategies

clinical topic updates
By Virginia Kaklamani, MD, DSc

HR+/HER2- Early Breast Cancer

Expert Perspectives® in HR+/HER2- Early Breast Cancer to Cover Key Topics in HR+/HER2- Early Breast Cancer Treatment

expert perspectives
By Ian Krop, MD, PhD; Melinda L. Telli, MD, FASCO